Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

NCT03399578 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
29
Enrollment
OTHER
Sponsor class

Stopped The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.

Conditions

Interventions

Sponsor

University of Oxford